Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
$81.63
$0.00
$35.11
$82.74
N/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$111.78
+0.0%
$107.12
$66.34
$119.96
$139.01B0.297.70 million shs6.96 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$53.38
-2.5%
$49.49
$30.82
$68.73
$1.90B0.76339,105 shs195,341 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$51.53
-3.0%
$49.96
$46.01
$83.62
$8.33B1.391.46 million shs2.10 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
0.00%0.00%0.00%0.00%0.00%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.45%+0.82%-0.60%+8.32%+67.61%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-2.49%+0.79%+6.72%+55.72%+14.50%
Bio-Techne Corp stock logo
TECH
Bio-Techne
-3.02%+0.16%+5.83%+5.57%-27.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/AN/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.833 of 5 stars
1.43.04.24.14.02.53.1
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.9856 of 5 stars
4.51.00.00.02.42.50.0
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.9706 of 5 stars
4.25.01.74.23.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
0.00
N/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.78
Moderate Buy$110.55-1.10% Downside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.09
Buy$96.7081.15% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0039.72% Upside

Current Analyst Ratings Breakdown

Latest TECH, IRON, AAAP, and GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$85.00
7/3/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$118.00
6/17/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$118.00
6/16/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
6/11/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$89.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/21/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/12/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.00
5/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
5/8/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$72.00 ➝ $63.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.84$6.87 per share16.27$15.44 per share7.24
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$14.85 per shareN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B6.97$2.24 per share22.97$13.13 per share3.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/A0.00N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.7523.5313.780.7220.76%51.93%17.40%8/6/2025 (Estimated)
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8262.8426.162.5310.89%13.17%10.17%8/6/2025 (Estimated)

Latest TECH, IRON, AAAP, and GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$0.99-$1.02-$0.03-$1.02N/AN/A
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.83%N/A66.53%10 Years
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.62%N/A39.02%N/A

Latest TECH, IRON, AAAP, and GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.16
1.37
1.23
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.04
37.65
37.65
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
4.24%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/ANot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3034.63 million33.17 millionNot Optionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

Is Bio-Techne Stock Underperforming the Nasdaq?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Advanced Accelerator Applications stock logo

Advanced Accelerator Applications NASDAQ:AAAP

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$111.78 +0.03 (+0.03%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$112.24 +0.46 (+0.41%)
As of 07/7/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$53.38 -1.37 (-2.50%)
As of 07/7/2025 04:00 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$51.53 -1.61 (-3.03%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$51.87 +0.34 (+0.66%)
As of 07/7/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.